All In Biotech

NDA 219943 · Astrazeneca

Koselugo

Selumetinib, Selumetinib Sulfate · Oral · Kinase Inhibitor

Priority reviewOrphan

Last checked: Nov 20, 2026Latest source record: May 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Sep 10, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

132

7 Phase 3, 8 recruiting

FAERS reports

1,684

1,358 serious, 103 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 26, 2026.

KOSELUGO is indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN) [see Dosage and Administration (2) ]. KOSELUGO is a kinase inhibitor indicated for the treatment of adult and pediatric patients 1 year of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). ( 1 )

Mechanism: Selumetinib is an inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). MEK1/2 proteins are upstream regulators of the extracellular signal-related kinase (ERK) pathway. Both MEK and ERK are critical components of the RAS-regulated RAF-MEK-ERK pathway, which is often activated in different types of cancers. In genetically modified mouse models of NF1 that generate neurofibromas that recapitulate the genotype and phenotype of human NF1, oral dosing of selumetinib inhibited ERK phosphorylation, and reduced neurofibroma numbers, volume, and proliferation.

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 10, 2025 Original approval · Type 3 - New Dosage Form · priority review OrphanLabelLetter
4 products under this application
  • KOSELUGO · SELUMETINIB 10MG · CAPSULE, ORAL · Prescription
  • KOSELUGO · SELUMETINIB SULFATE EQ 5MG BASE · GRANULE, ORAL · Prescription
  • KOSELUGO · SELUMETINIB 25MG · CAPSULE, ORAL · Prescription
  • KOSELUGO · SELUMETINIB SULFATE EQ 7.5MG BASE · GRANULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Selumetinib" as an intervention, any sponsor and status, largest first.

All 132 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash140
  • off label use121
  • blood creatine phosphokinase increased104
  • paronychia96
  • diarrhoea92
  • acne85
  • dermatitis acneiform84
  • nausea84
  • fatigue82
  • alopecia70
  • vomiting67
  • death57

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20081
20091
20101
20115
20124
20131
20142
20155
20167
20174
20185
20191
202055
202197
2022168
2023191
2024351
2025379
2026405

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Koselugo (Selumetinib Sulfate)

2024 spending

$22.4M

Beneficiaries

157

1,175 claims

Per beneficiary

$142,431

$182.85 per unit

View as table
YearSpending
2020$3,507,793
2021$8,545,575
2022$10,000,943
2023$14,917,273
2024$22,361,712

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 110 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.